• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Request Free Sample

    ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    UK Glioblastoma Market

    ID: MRFR/HC/48099-HCR
    200 Pages
    Garvit Vyas
    September 2025

    UK Glioblastoma Market Research Report By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy), By Drug Type (Temozolomide, Bevacizumab, Carmustine, Nivolumab, Lomustine), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy) andBy End User (Hospitals, Clinical Research Organizations, Homecare Settings)- Forecast to 2035

    Share:

    Download PDF

    ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    UK Glioblastoma Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    UK Glioblastoma Market Summary

    The United Kingdom Glioblastoma market is projected to experience steady growth from 142.7 USD Million in 2024 to 257 USD Million by 2035.

    Key Market Trends & Highlights

    UK Glioblastoma Key Trends and Highlights

    • The market is expected to grow at a compound annual growth rate (CAGR) of 5.5 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 257 USD Million, indicating a robust increase.
    • In 2024, the market is valued at 142.7 USD Million, reflecting the current demand for glioblastoma treatments.
    • Growing adoption of innovative treatment options due to increasing awareness of glioblastoma is a major market driver.

    Market Size & Forecast

    2024 Market Size 142.7 (USD Million)
    2035 Market Size 257 (USD Million)
    CAGR (2025-2035) 5.5%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Genentech, Celgene, Novartis, AstraZeneca, Merck, Eli Lilly, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Pfizer, Amgen, Roche, AbbVie, Sanofi, Incyte Corporation, Bayer

    UK Glioblastoma Market Trends

    The UK Glioblastoma Market is experiencing significant growth driven by an increasing incidence of glioblastoma multiforme, particularly among the aging population. As the UK population continues to age, the prevalence of glioblastoma is expected to rise, leading to a greater demand for effective treatments. Innovative therapies, including targeted drug delivery systems and personalized medicine approaches, are emerging as key market drivers, offering more tailored and effective treatment solutions to patients.

    Additionally, advancements in surgical techniques and technology play a vital role in improving patient outcomes, thus propelling the market further.Immunotherapy and combination treatments offer immune focus culminating opportunities for drug developers and biotechnology firms in the UK. The NHS undertakes R&D monumentally, seeking to devise new therapeutical solutions fostering “collaboration and innovation.” There is an increase in the use of new treatments and the preparedness to participate in clinical trials, which is indicative of active interest by both patients and providers, suggesting that new therapies can be easily integrated into practice.

    Recently, there has been a tendency towards the use of less invasive diagnostic approaches – liquid biopsies and sophisticated imaging which may facilitate better early detection and tracking of glioblastoma.This trend is significant as it allows for timely interventions and enhances treatment effectiveness. Furthermore, the growing emphasis on patient-centered care and supportive therapies is reshaping treatment paradigms, reflecting a holistic approach to glioblastoma management in the UK. The concerted efforts in research, public health initiatives, and policy reforms signify that the UK Glioblastoma Market is evolving rapidly, with promising developments ahead.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    UK Glioblastoma Market Drivers

    Market Segment Insights

    Glioblastoma Market Treatment Type Insights

    The UK Glioblastoma Market is characterized by distinct Treatment Types, each playing a crucial role in patient management and outcomes. Surgery remains a fundamental approach, often viewed as the first-line treatment. This modality seeks to remove as much of the tumor as possible, significantly impacting overall survival rates and quality of life for patients. Following surgery, Radiation Therapy is frequently employed to target residual cancerous cells, which further supports the disruption of tumor recurrence. Moreover, Chemotherapy is integral to the treatment regimen, with various agents utilized to inhibit tumor growth and metastasis, enhancing therapeutic efficacy.

    Targeted Therapy is gaining traction within the UK Glioblastoma Market, focusing on specific molecular targets present within tumor cells, leading to more personalized treatment plans. This approach is vital as it allows for the development of therapies that minimize damage to healthy cells while maximizing the therapeutic impact on glioblastoma. Additionally, Immunotherapy has emerged as a novel approach, harnessing the body’s immune system to combat malignancies.

    Its significance lies in its potential to provide longer-lasting responses and improve survival rates, representing a significant shift in treatment paradigms.The diversity of these treatment types illustrates the complexities and the multifaceted approach needed to tackle glioblastoma. Each treatment type holds importance depending on the individual case and progression of the disease, illustrating the dynamic landscape of the UK Glioblastoma Market. The market's expansion is supported by continuous advancements in Research and Development, as well as an increasing emphasis on personalized medicine approaches tailored to specific patient profiles.

    The interplay between these treatment modalities contributes to improved patient outcomes and reflects the ongoing need for innovation in therapies addressing glioblastoma in the UK. Overall, the Treatment Type segment is not only foundational for clinical practice but is also a critical area of focus for ongoing research, ensuring that patients receive the most effective and appropriate interventions based on the latest advancements in oncology.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Glioblastoma Market Drug Type Insights

    The UK Glioblastoma Market, specifically within the Drug Type segment, reflects a landscape where various treatment options demonstrate unique characteristics and importance. Temozolomide has emerged as a cornerstone treatment for glioblastoma due to its oral administration and efficacy, significantly impacting patient management in the UK. Bevacizumab, with its targeted mechanism, plays a critical role in inhibiting tumor vascularization, thus showing the potential to improve overall survival rates for patients in the UK.

    Carmustine remains significant due to its chemotherapeutic properties, while Nivolumab represents a shift towards immunotherapy approaches, enhancing the therapeutic options available to oncologists.Lomustine adds to the diversity of treatment protocols by providing a different pharmacological pathway. The ongoing development of these medications reflects the broader trends in the UK Glioblastoma Market, such as the need for effective therapies that manage the aggressive nature of this malignancy. Further research and development continue to focus on refining treatment protocols and exploring combination therapies, aiming to meet the rising demand for advanced care in managing glioblastoma effectively.

    As the UK population ages and the incidence of the disease rises, the Drug Type segment may face both opportunities for growth and challenges regarding patient access and treatment personalization.

    Glioblastoma Market Distribution Channel Insights

    The Distribution Channel segment of the UK Glioblastoma Market plays a crucial role in ensuring the availability of treatments for patients diagnosed with this aggressive form of brain cancer. This segment is characterized by diverse channels including Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Specialty Pharmacy, each contributing uniquely to the market dynamics. Hospital Pharmacies are pivotal as they often provide specialized therapies and medications tailored to inpatient care, thus significantly impacting patient outcomes.

    Retail Pharmacies serve as accessible points for patients to obtain prescription medications, while Online Pharmacies are becoming increasingly significant due to their convenience and the ability to reach patients in remote areas. Specialty Pharmacies focus on high-cost biologics and complex therapies, often providing patient education and management services, which is essential for conditions like Glioblastoma that require comprehensive treatment approaches. The growing prevalence of Glioblastoma and advancements in treatment options drive the demand across these channels, creating opportunities for improved patient care and access to necessary therapies.

    As the market continues to evolve, the Distribution Channel segment is expected to adapt to changing patient needs, regulatory landscapes, and technological advancements that influence how medications are dispensed and managed across the UK.

    Glioblastoma Market End User Insights

    The End User segment of the UK Glioblastoma Market exhibits a diverse array of applications, prominently featuring Hospitals, Clinical Research Organizations, and Homecare Settings. Hospitals play a critical role, as they are the primary destinations for diagnosis and treatment, offering specialized facilities and advanced technologies for glioblastoma care. Clinical Research Organizations drive innovation by conducting essential clinical trials that contribute to the development of new therapies and improve treatment protocols, which is vital for addressing the complex dynamics of glioblastoma.

    Meanwhile, Homecare Settings are gaining traction, facilitating patient-centered care and enabling patients to receive treatment in familiar environments, which can enhance their quality of life. This segment's significance is underscored by the rising incidence of glioblastoma in the UK and the ongoing need for specialized care and tailored treatment approaches in response to patient demographics.

    Insights into the UK Glioblastoma Market segmentation reflect a strong demand for streamlined patient management and integrated services across these key areas, ensuring that patients receive comprehensive care that meets their unique needs.The evolving landscape reveals opportunities for growth driven by advancements in healthcare delivery and technology integration within these settings.

    Get more detailed insights about UK Glioblastoma Market

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The UK Glioblastoma Market is a dynamic and competitive arena characterized by a blend of established pharmaceutical companies and emerging biotechnology firms that are actively engaged in the treatment of this aggressive form of brain cancer. Stakeholders within this market face the ongoing challenge of innovating therapies that can enhance patient outcomes while navigating the complex regulatory landscape. The competitive landscape is influenced by factors such as the advancement of novel treatment modalities, strategic partnerships, and the high unmet medical need that continues to drive research and development efforts.

    As the market evolves, companies are increasingly focusing on personalized medicine and targeted therapies, reflecting a shift toward optimizing treatment approaches based on individual patient profiles.Genentech has maintained a robust presence in the UK Glioblastoma Market, leveraging its extensive research capabilities and a strong portfolio of innovative therapies. The company is known for its commitment to advancing treatments for neurological conditions, and its strengths lie in its rich pipeline and focus on understanding the underlying biology of glioblastoma.

    Genentech's ability to conduct comprehensive clinical trials has also contributed to its competitive edge, allowing the firm to stay at the forefront of medical advancements. With a dedication to patient needs and collaboration with healthcare providers, Genentech plays a pivotal role in the ongoing efforts to improve survival rates and enhance the quality of life for glioblastoma patients in the UK.Celgene operates within the UK Glioblastoma Market with a strategic emphasis on developing targeted therapies aimed at managing brain tumors.

    The company has built a reputation for delivering high-quality treatments that address the specific needs of glioblastoma patients and boasts a portfolio that includes cutting-edge products aimed at modulating the immune response and inhibiting tumor growth. Celgene's strengths in the market are backed by its strong commitment to research and development, as well as its ability to form valuable partnerships that enhance its therapeutic offerings.

    The firm has actively sought mergers and acquisitions that align with its mission to expand its capabilities and market presence in the UK, further solidifying its role as a key player in addressing the urgent therapeutic challenges posed by glioblastoma. As the demand for effective treatments continues to rise, Celgene's strategic initiatives position it for continued influence within this critical segment of the healthcare market.

    Key Companies in the UK Glioblastoma Market market include

    Industry Developments

    Market Segmentation

    Outlook

    • Hospitals
    • Clinical Research Organizations
    • Homecare Settings

    Glioblastoma Market End User Outlook

    • Hospitals
    • Clinical Research Organizations
    • Homecare Settings

    Glioblastoma Market Drug Type Outlook

    • Temozolomide
    • Bevacizumab
    • Carmustine
    • Nivolumab
    • Lomustine

    Glioblastoma Market Treatment Type Outlook

    • Surgery
    • Radiation Therapy
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy

    Glioblastoma Market Distribution Channel Outlook

    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Specialty Pharmacy

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 134.82(USD Million)
    MARKET SIZE 2024 142.67(USD Million)
    MARKET SIZE 2035 257.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 5.496% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Genentech, Celgene, Novartis, AstraZeneca, Merck, Eli Lilly, BristolMyers Squibb, Regeneron Pharmaceuticals, Pfizer, Amgen, Roche, AbbVie, Sanofi, Incyte Corporation, Bayer
    SEGMENTS COVERED Treatment Type, Drug Type, Distribution Channel, End User
    KEY MARKET OPPORTUNITIES Targeted therapies development, Advanced diagnostic tools, Personalized medicine approaches, Clinical trial innovations, Early detection screenings
    KEY MARKET DYNAMICS increased incidence rates, innovative treatment options, high research funding, unmet medical needs, supportive care advancements
    COUNTRIES COVERED UK

    Market Highlights

    Author

    Garvit Vyas
    Analyst

    Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

    Get In Touch

    Leave a Comment

    FAQs

    What is the expected market size of the UK Glioblastoma Market in 2024?

    The UK Glioblastoma Market is expected to be valued at 142.67 million USD in 2024.

    What will be the market size of the UK Glioblastoma Market by 2035?

    By 2035, the overall UK Glioblastoma Market is projected to reach 257.0 million USD.

    What is the expected CAGR for the UK Glioblastoma Market from 2025 to 2035?

    The expected CAGR for the UK Glioblastoma Market from 2025 to 2035 is 5.496%.

    Which treatment type is expected to have the largest market share in 2024?

    In 2024, Radiation Therapy is expected to hold the largest market share valued at 40.0 million USD.

    What will the market size for Surgery be in the UK Glioblastoma Market by 2035?

    The market size for Surgery in the UK Glioblastoma Market is projected to reach 55.0 million USD by 2035.

    Who are the major players in the UK Glioblastoma Market?

    Major players in the UK Glioblastoma Market include Genentech, Celgene, Novartis, AstraZeneca, and Merck.

    What is the expected market value of Chemotherapy in 2024?

    The expected market value of Chemotherapy in the UK Glioblastoma Market in 2024 is 35.0 million USD.

    What are the growth drivers for the UK Glioblastoma Market?

    The growth drivers for the UK Glioblastoma Market include advancements in treatment options and increasing awareness.

    What challenges may impact the UK Glioblastoma Market in the coming years?

    Potential challenges for the UK Glioblastoma Market include high treatment costs and the complexity of disease management.

    How will Immunotherapy's market size change from 2024 to 2035?

    Immunotherapy's market size is expected to grow from 12.67 million USD in 2024 to 17.0 million USD by 2035.

    1. |- Table of Contents   EXECUTIVE SUMMARY Market Overview Key Findings Market Segmentation Competitive Landscape Challenges and Opportunities Future Outlook     MARKET INTRODUCTION Definition Scope of the study Research Objective Assumption Limitations RESEARCH METHODOLOGY Overview Data Mining Secondary Research Primary Research Primary Interviews and Information Gathering Process Breakdown of Primary Respondents Forecasting Model Market Size Estimation Bottom-Up Approach Top-Down Approach Data Triangulation Validation     MARKET DYNAMICS Overview Drivers Restraints Opportunities MARKET FACTOR ANALYSIS Value chain Analysis Porter's Five Forces Analysis Bargaining Power of Suppliers Bargaining Power of Buyers Threat of New Entrants Threat of Substitutes Intensity of Rivalry COVID-19 Impact Analysis Market Impact Analysis Regional Impact Opportunity and Threat Analysis     UK Glioblastoma Market, BY Treatment Type (USD Million) Surgery Radiation Therapy Chemotherapy Targeted Therapy Immunotherapy UK Glioblastoma Market, BY Drug Type (USD Million) Temozolomide Bevacizumab Carmustine Nivolumab Lomustine UK Glioblastoma Market, BY Distribution Channel (USD Million) Hospital Pharmacy Retail Pharmacy Online Pharmacy Specialty Pharmacy UK Glioblastoma Market, BY End User (USD Million) Hospitals Clinical Research Organizations Homecare Settings     Competitive Landscape Overview Competitive Analysis Market share Analysis Major Growth Strategy in the Glioblastoma Market Competitive Benchmarking Leading Players in Terms of Number of Developments in the Glioblastoma Market Key developments and growth strategies New Product Launch/Service Deployment Merger & Acquisitions Joint Ventures Major Players Financial Matrix Sales and Operating Income Major Players R&D Expenditure. 2023 Company Profiles Genentech Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Celgene Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Novartis Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies AstraZeneca Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Merck Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Eli Lilly Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies BristolMyers Squibb Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Regeneron Pharmaceuticals Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Pfizer Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Amgen Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Roche Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies AbbVie Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Sanofi Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Incyte Corporation Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Bayer Financial Overview Products Offered Key Developments SWOT Analysis Key Strategies Appendix References Related Reports LIST Of tables   LIST OF ASSUMPTIONS UK Glioblastoma Market SIZE ESTIMATES & FORECAST, BY TREATMENT TYPE, 2019-2035 (USD Billions) UK Glioblastoma Market SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2035 (USD Billions) UK Glioblastoma Market SIZE ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD Billions) UK Glioblastoma Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions) PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL ACQUISITION/PARTNERSHIP                                                           LIST Of figures   MARKET SYNOPSIS UK GLIOBLASTOMA MARKET ANALYSIS BY TREATMENT TYPE UK GLIOBLASTOMA MARKET ANALYSIS BY DRUG TYPE UK GLIOBLASTOMA MARKET ANALYSIS BY DISTRIBUTION CHANNEL UK GLIOBLASTOMA MARKET ANALYSIS BY END USER KEY BUYING CRITERIA OF GLIOBLASTOMA MARKET RESEARCH PROCESS OF MRFR DRO ANALYSIS OF GLIOBLASTOMA MARKET DRIVERS IMPACT ANALYSIS: GLIOBLASTOMA MARKET RESTRAINTS IMPACT ANALYSIS: GLIOBLASTOMA MARKET SUPPLY / VALUE CHAIN: GLIOBLASTOMA MARKET GLIOBLASTOMA MARKET, BY TREATMENT TYPE, 2025 (% SHARE) GLIOBLASTOMA MARKET, BY TREATMENT TYPE, 2019 TO 2035 (USD Billions) GLIOBLASTOMA MARKET, BY DRUG TYPE, 2025 (% SHARE) GLIOBLASTOMA MARKET, BY DRUG TYPE, 2019 TO 2035 (USD Billions) GLIOBLASTOMA MARKET, BY DISTRIBUTION CHANNEL, 2025 (% SHARE) GLIOBLASTOMA MARKET, BY DISTRIBUTION CHANNEL, 2019 TO 2035 (USD Billions) GLIOBLASTOMA MARKET, BY END USER, 2025 (% SHARE) GLIOBLASTOMA MARKET, BY END USER, 2019 TO 2035 (USD Billions) BENCHMARKING OF MAJOR COMPETITORS  

    UK Glioblastoma Market Segmentation

    • Glioblastoma Market By Treatment Type (USD Million, 2019-2035)

      • Surgery
      • Radiation Therapy
      • Chemotherapy
      • Targeted Therapy
      • Immunotherapy

     

    • Glioblastoma Market By Drug Type (USD Million, 2019-2035)

      • Temozolomide
      • Bevacizumab
      • Carmustine
      • Nivolumab
      • Lomustine

     

    • Glioblastoma Market By Distribution Channel (USD Million, 2019-2035)

      • Hospital Pharmacy
      • Retail Pharmacy
      • Online Pharmacy
      • Specialty Pharmacy

     

    • Glioblastoma Market By End User (USD Million, 2019-2035)

      • Hospitals
      • Clinical Research Organizations
      • Homecare Settings

     

     

     

     

     

     

    Report Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027